The success of genetically engineered T cells that express chimeric antigen receptors (CARTs) has been a momentous step forward in harnessing the potent cancer fighting abilities of the immune system. The efficacy seen in relapsed/refractory (r/r) acute lymphoblastic leukaemia (ALL), not only by inducing remission, but also in maintaining long-term disease control, has been unprecedented. While the foundation for this approach has been firmly set in place, continued development will improve the efficacy, toxicity and applicability to other malignancies of this new class of 'living drugs'. In this review, we provide a comprehensive overview of the most current clinical trial data in both acute and chronic leukaemias, and discuss some of the potential ways to enhance the activity and safety of CART therapy going forward.
Background
A lymphocyte's capacity for fighting cancer is well recognized as evidenced by the use of donor lymphocyte infusions (DLI) for relapsed haematological malignancies following allogeneic stem cell transplant (allo-SCT) (Porter et al, 2010) , the expansion and re-infusion of tumour infiltrating lymphocytes in solid tumours (TILs) (Goff et al, 2016) , and most recently through immune checkpoint blockade to treat various types of tumours (Topalian et al, 2012) . However, these approaches come with significant limitations: DLI, while offering the benefit of graft-versus-leukaemia (GVL), also come with the risk of graft-versus-host disease (GVHD). The expansion of TILs is laborious, technically challenging, and relies on the identification and expansion of T cells specific for tumour antigens from individual patients. The efficacy of immune checkpoint blockade is predominantly in tumours with high mutational burdens that result in neo-antigens capable of recognition by endogenous T cells that are actively inhibited by an immune-suppressive tumour microenvironment (TME) (Gubin et al, 2014; Tumeh et al, 2014; McGranahan et al, 2016) .
T cells that express chimeric antigen receptors (CARTs) have the ability to overcome many of the inherent limitations in these other forms of immunotherapy. Chimeric Antigen Receptors (CARs) are synthetic polypeptides consisting of an extracellular single chain variable fragment (scFv) directed against an antigen on a tumour cell, a hinge region, transmembrane domain and an intracellular signalling domain . T cells can be genetically engineered using retroviral or lentiviral vectors to permanently express this construct on the cell surface, thereby allowing them to recognize extracellular tumour antigens in a major histocompatibility complex (MHC) independent manner. While combining the non-MHC restricted specificity of an antibody with the potent cytotoxicity and proliferative capacity of T cells was an elegant theory from conception (Gross et al, 1989) , early success was hindered due to lack of T cell expansion, persistence and resulting anergy upon engagement with cognate antigen (Jensen et al, 2010; Savoldo et al, 2011) . This was largely due to the inability of the first generation CARs to adequately activate T cells in the immune-suppressive TME, especially when tumour cells lacked expression of costimulatory molecules Joyce & Fearon, 2015) , although lack of lymphodepleting therapy in this setting may also have played a role (Yao et al, 2012) . A significant breakthrough came with the insertion of a costimulatory domain into this construct; thereby augmenting the intracellular signalling cascade allowing for significantly increased expansion and persistence of the T cells (Maher et al, 2002; Milone et al, 2009; Zhao et al, 2009) . These vastly improved 'second generation CARs' most often employ 4-1BB (also termed TNFRSF9, or CD137) or CD28 as the co-stimulatory molecule, and are currently the leading candidates in clinical trials across the globe in many haematological and solid malignancies (Maus et al, 2014; Gill et al, 2016) . Newer third and fourth generation CARs are being developed that may possess enhanced potency by combining co-stimulatory domains in a single cell, or introducing other molecules such as OX40 (also termed TNFRSF4) or ICOS (Till et al, 2012; Guedan et al, 2014) . Whether this will translate into improved clinical activity remains to be proven.
CARTs directed against CD19
CD19 is an attractive target for several reasons including its ubiquitous cell surface expression from early pre-B cells to mature B cells before down regulation on terminally differentiated plasma cells (Scheuermann & Racila, 1995) . It continues to be expressed by B cell malignancies including acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), non-Hodgkin Lymphoma (NHL), and might even be relevant to the pathological process of multiple myeloma (Garfall et al, 2015) . Importantly, the antigen is only expressed on B cells, thereby preventing significant non-haematological toxicity while the expected on-target toxicity of B cell aplasia is manageable.
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia remains the most commonly diagnosed chronic leukaemia of adults with almost 19 000 cases diagnosed per year (National Cancer Institute [NCI] 2016). While many patients have an indolent course, patients who have high-risk disease, or progress with short treatmentfree intervals continue to have extremely poor outcomes and limited survival (Zenz et al, 2012; Pflug et al, 2014) . While the only identified cure for CLL is allo-SCT, many patients with relapsed/refractory (r/r) CLL are not candidates for transplant because of age, co-morbidity, lack of suitable donor, or anticipated limited success due to heavy disease burden (Mato & Porter, 2015) .
Chronic lymphocytic leukaemia is the first disease in which the potential of the second generation CARTs was realized. The Memorial Sloan Kettering Cancer Center (MSKCC) group administered CARTs with an scFv to CD19 and CD28 co-stimulatory domain to eight patients with chemotherapy-refractory CLL (Brentjens et al, 2011) . While efficacy was limited to one patient with a partial response (PR) and two with stable disease (SD), it was shown that these T cells could traffic to all areas of leukaemic involvement, including blood, bone marrow (BM), lymph nodes and organs, while persisting up to several weeks in the patients who received lymphodepleting therapy.
The initial outcomes using an scFv to CD19 and a 4-1BB co-stimulatory domain in refractory CLL appeared more promising. Two out of the first three patients reported by our group at the University of Pennsylvania (PENN) achieved complete remission (CR), and the third patient a significant PR Porter et al, 2011) . These initial reports demonstrated massive in-vivo proliferation, trafficking to and eradication of bulky tumour, and longterm functional persistence; all critically important determinants of anti-tumour efficacy using adoptive T cell immunotherapy. Mature data from this clinical trial of 14 patients has since been reported with a 57% overall response rate (ORR) (4 CR, 4 PR) . Those who achieved CR were also minimal residual disease (MRD) negative, and no patient who achieved CR relapsed with >4 years follow-up. CARTs could be identified from peripheral blood by flow cytometry and polymerase chain reaction almost 3 years after initial infusion, and demonstrated on-going functionality with cytokine production and degranulation in response to CD19 antigen ex-vivo. The only factors that correlated with response were the degrees of expansion and persistence of CARTs.
Outcomes from the NCI using 19-CD28f CARTs are also promising. Three out of four patients achieved durable CRs that were on-going from 14 to 23 months . Interestingly, one patient had recovery of circulating polyclonal B-cells 13 months after CART infusion, yet remained in on-going CR for 23+ months.
In compilation, these data highlight the potency of CARTs in r/r CLL and the impressive durability in patients achieving CR. This approach may be feasible in many patients not eligible for transplant as it does not require a matched donor, avoids the risks of a conditioning regimen, can be used with heavy tumour burdens at time of treatment, while potentially providing on going immuno-surveillance without the concerns of developing GVHD. While relatively few patients have been treated to date, future studies are underway to understand both patient and product characteristics that will define and predict activity/response in order to build upon this early success.
Acute lymphoblastic leukaemia
ALL is the most common malignancy of children and teenagers in the United States, and the most frequent cause of cancer-related death before the age of 20 (Hunger & Mullighan, 2015) . Newly diagnosed children treated with standard multimodal therapy have a 90% 5-year overall survival (OS) , but those who fail induction therapy or relapse after initial remission have poor outcomes (Ko et al, 2010; Schrappe et al, 2012) . Adults with ALL have a poor prognosis, as up to 50% of patients relapse after achieving an initial CR, and adult patients with r/r disease have <10% 5-year OS (Fielding et al, 2007; Forman & Rowe, 2013) . Given that most patients with r/r ALL have chemotherapy resistant disease, the pursuit of effective novel agents with alternative mechanism of action is critical (Frey & Luger, 2015) .
Clinical trials using CARTs to CD19 in r/r ALL have shown unprecedented success, with remission rates of 70-93% (Table I) (Davila et al, 2014; Maude et al, 2014; Lee et al, 2015; Turtle et al, 2016) . Our group at PENN and the Children's Hospital of Philadelphia (CHOP), demonstrated a 90% CR rate at one month post-CART infusion in 30 (5 adult, 25 paediatric) r/r ALL patients (Maude et al, 2014) . Twenty-two of the 25 patients evaluated for MRD using a multi-parametric flow cytometry based assay were negative (MRD À ), and 3 demonstrated very low levels of disease.
Review
Despite 18 out of the 30 patients being post allo-SCT, T cells were successfully collected and manufactured from the recipient and did not lead to GVHD. The probability of CART persistence was 68%, event-free survival 67% and OS 78% at 6 months. Disease-free survival was ongoing at 24 months for 19 patients, with 15 out of 19 not receiving further therapy as only three patients proceeded to allo-SCT. Similar to the CLL trial at PENN, the failure of CARTs to proliferate was associated with lack of response. Between 6 weeks and 8Á5 months, four patients relapsed with CD19 + lymphoblasts correlating with loss of CART persistence, and three had CD19 À disease indicating a potential tumour escape mechanism. The Fred Hutchinson Cancer Center (FHCC) reported outcomes in adult r/r ALL using a 19-4-1BBf CART in which they attempted to use CD8 + central memory subset for manufacture and then infuse a 1:1 CD4:CD8 product, based on preclinical data indicating a synergistic enhancement in potency with this strategy. Thirty patients were treated following lymphodepletion with cyclophosphamide (Cy) with or without fludarabine (Flu). Efficacy mirrored other studies (Davila et al, 2014; Maude et al, 2014; Lee et al, 2015) A similarly high remission rate was demonstrated in a MSKCC study using a 19-CD28f CART. Sixteen r/r adult ALL patients, were treated with salvage chemotherapy followed by Cy for lymphodepletion. Eighty-eight per cent of patients achieved CR, with the majority of responders being MRD À (12/14). Seven out of 10 patients eligible for allo-SCT proceeded, and none of these patients relapsed with followup extending to 24 months. In patients not receiving allo-SCT, CARTs were shown to persist for up to 3 months (Davila et al, 2014) . The NCI, also using a 19-CD28f CART in 21 children and young adults (20 with ALL, 1 with NHL), administered following Cy/Flu, showed a 70% CR (14/20) rate in patients with B cell ALL, 60% (12/20) achieved CR MRD À status, 10 patients proceeded to allo-SCT, and at 9Á7 months the OS was 51Á6%. CART persistence was limited up to 68 days post-CART infusion (Lee et al, 2015) . Taken together, these data highlight the remarkable potency of CART19 for ALL by eradicating even MRD in most patients. Relapse remains a major limitation, but remissions are sustained in some patients even without subsequent allo-SCT. Therefore, CAR T cells are easily one of the most potent and effective approaches for patients with r/r ALL. Whether CARTs can or should be applied earlier in the disease course and their use in relation to allo-SCT remains to be determined, and will be the subject of upcoming trials .
CART19 associated toxicities
While CARTs have demonstrated impressive efficacy, they come with several serious toxicities unique to this class of therapies. As clinical trials expand, and as CARTs move into the mainstream, understanding, predicting and improving the management of these toxicities will be crucial. Since CARTs targeting CD19 have the most clinical data to date, we focus on toxicities seen with this particular CART. It can be expected that CARTs aimed at other antigen targets will have some overlapping, but also individual toxicities.
Cytokine release syndrome
Cytokine release syndrome (CRS) is a marked inflammatory systemic response due to dramatic increases in many cytokines that occur with the in-vivo activation and exponential proliferation of CARTs, usually within days of initial infusion (Fig 1) (Grupp et al, 2013; Lee et al, 2014) . Initial clinical hallmarks of this phenomenon include pyrexia and flu-like symptoms that can progress to severe CRS (sCRS) with vasodilatory shock, capillary leak and respiratory compromise, requiring Intensive Care Unit level care. The majority of patients will experience CRS, and 27-64% will experience sCRS, although the definitions of severity vary across studies, and can be confounded by concurrent infectious processes (Table I) (Davila et al, 2014; Maude et al, 2014; Lee et al, 2015; Turtle et al, 2016) . Commonly seen laboratory derangements include hyperferritinemia with levels often >10 000 lg/l and sometimes >100 000 lg/l, elevated C reactive protein (CRP), and low fibrinogen. In addition, profound elevations in interleukin-6 (IL6), interferon-c (IFN-c), and soluble interleukin 2-receptor a (sIL2Ra) among many cytokines are reported.
Investigation using clinical and laboratory data is underway in an attempt to identify markers that not only correlate, but can predict development of sCRS. Although results from these studies are variable, partly due to heterogeneous products and trial designs, there is accumulating evidence that (i) cell dosage, (ii) tumour burden, (iii) use of lymphodepleting therapy and (iv) increased peak of CART proliferation/kinetics, can all play an influential role in CRS (Brentjens et al, 2010; Davila et al, 2014; Maude et al, 2014; Lee et al, 2015; Porter et al, 2015) . Looking to further identify predictive risk factors that may allow pre-emptive treatment strategies, our centre has performed an in-depth analysis on 51 patients who received CART19 for ALL, and had serial measurements in the first month after T cell infusion (Teachey et al, 2016) . Twenty-three cytokines were significantly altered when comparing grade 4-5 vs. grade 0-3 CRS, and combinations of select values used to predict sCRS demonstrated good sensitivity and specificity in a validation cohort.
It was recognized early in CART development that IL6 is markedly increased in patients with CRS, and is probably central to CRS pathophysiology. An anti IL6 receptor antagonist, tocilizumab, has been successfully used to rapidly improve CRS in most patients (Grupp et al, 2013 ). In contrast to steroids, tociluzimab has limited toxicity with no known direct lymphotoxic effects, making it an attractive choice to treat CRS without mitigating the antitumour effect of the CARTs (Davila et al, 2014; Maude et al, 2014) . Strategies to further optimize treatment algorithms, including optimization of tocilizumab administration timing for CRS are currently under investigation (NCT 02906371).
Neurological
Neurological toxicities seen in patients who receive CART19 include delirium, encephalopathy and seizures. Whether directly due to T cell-mediated toxicity, profoundly elevated inflammatory cytokines that are produced systemically and then transverse the blood brain barrier, or produced directly within the central nervous system , remains Fig 1. A potential road to cytokine release syndrome. Ag, antigen; APC, antigen presenting cell; CARTs, chimeric antigen receptor T cells; CRP, c-reactive protein; IFN-c, interferon gamma; IL1, interleukin-1; IL2, interleukin-2; IL6, interleukin-6; IL6R, interleukin-6 receptor; IL8, interleukin-8; MIP, macrophage inflammatory protein; MCP1, monocyte chemoattractant protein; sCRS, severe cytokine release syndrome; Tc, cytotoxic T cell; Th1, T helper 1 cells; TNF-a, tumour necrosis factor alpha.
unclear. In our reported study, 17/19 evaluable patients had detectable CARTs in their cerebrospinal fluid when assessed at day 28, but only a subset developed neurological toxicity (Maude et al, 2014) . Clinical symptoms do not seem to correlate precisely with that of systemic CRS, and do not respond in the same way to anti-IL6 receptor directed therapy although the FHCC study noted on multivariate analysis that a serum IL6 concentration of ≥30 pg/ml on day 1 along with disease burden were independent predictors of more severe neurological events .
B cell aplasia
B cell aplasia and resulting hypogammaglobulinaemia correlates with CART engraftment and persistence thereby making it a useful biological marker for functional CART persistence (Maude et al, 2014; Porter et al, 2015) . The biggest risk for on-going B cell aplasia is opportunistic infections, but can this can be mitigated through monitoring and repletion of immunoglobulins. Long-term outcomes of patients with persistent B cell aplasia from CART19 being managed with this approach are not yet available, although significantly increased rates of serious infections have not been noted to date.
CARTs in acute myeloid leukaemia
Despite improvement in our understanding of acute myeloid leukaemia (AML) biology, poor outcomes remain due to both disease-related and treatment-related mortality, with a 25-40% 5-year OS for patients with newly diagnosed AML, and a 5-year OS as low as 10% after first relapse (Breems et al, 2005; Forman & Rowe, 2013) . The limited successes and high toxicity observed with currently available strategies indicate an urgent need for novel therapeutics. Given the successes observed in ALL, it is therefore natural to consider CARTs for AML. The biggest hurdle is identifying an appropriate surface antigen target, as those known to be present on transformed neoplastic cells are also present on healthy haematopoietic stem cells predicting for BM aplasia. Despite this challenge, several potential CART targets are being actively explored in clinical trials including (i) CD33 (NCT 01864902) (ii) CD123 (NCT 02159495, NCT 02623582) (iii) Lewis Y antigen (LeY; NCT 01716364) and other targets including Folate Receptorb (FRb) are in pre-clinical testing with some promising preliminary results.
CD123
While CD123 is constitutively expressed on healthy haematopoietic cells, leukaemic cells often up-regulate this antigen (Jordan et al, 2000) , and this differential expression may allow for a narrow therapeutic window. However, significant concern remains that the persistence of CARTs targeting CD123 could lead to irreversible myeloablation. In addition, CD123 is expressed on non-haematological tissue, including endothelial cells, which may lead to additional toxicity (Brizzi et al, 1993) . A 123-CD28f CART at City of Hope, and 123-4-1BBf CART at PENN, have both demonstrated potent leukaemia killing ability in pre-clinical models, but have produced inconsistent results with regard to the myeloablative effect on healthy CD123 + cells (Mardiros et al, 2013; Gill et al, 2014 ). An on-going phase I study at City of Hope (NCT02159495) using lentivirally transduced CD28f CARTs include a truncated EGFR placed in the CART allowing for cetuximab-induced suicide if required (Mardiros et al, 2015) . Our currently ongoing phase I trial at PENN (NCT 02623582) takes a different approach by using repeated infusions of an mRNA transduced CART which results in only transient CAR expression because there is no permanent genome modification. Both studies require subjects to have an available donor for allo-SCT in the case of myeloablation.
CD33
CD33 has heterogeneous expression on leukaemia blasts dependent on the maturation status of the initially transformed haematopoietic cell (Walter et al, 2012) . Approximately 75% of patients will have blasts that are CD33 + , but it should be noted that there are CD33 splice variants that impact protein structure, which may not be recognized by current CD33 directed therapeutics (Laszlo et al, 2016) . Also, complicating CD33 as a target is its presence on healthy myeloid cells within the BM, and other tissues, such as resident macrophages in the liver. Therefore, on target off tumour toxicity is predicted. Pre-clinical testing has shown a potent anti-leukaemia effect with a humanized anti-CD33 CART, but at the cost of significant myelotoxicity (Kenderian et al, 2015) . One published report from the Chinese PLA General Hospital using CD33 directed 4-1BBf CARTs delivered in escalating fractions to a single patient with refractory AML lead to a transient response .
Lewis Y antigen
CARTs have the remarkable ability to recognize non-protein antigens, further broadening the landscape of targets. An example of this is the Lewis Y Antigen (LeY), an oligosaccharide structurally related to the Lewis blood group antigens, but with limited expression on other normal healthy tissues (Yuriev et al, 2005) . It is found on tumour-associated antigens on multiple types of cancer including AML (Ritchie et al, 2013) . A retrovirally transduced LeY-CD28f CART has been infused after lymphodepletion to four patients (Ritchie et al, 2013 
Folate receptor b
The folate receptor b (FRb) is primarily found on myeloidlineage haematopoietic cells and is frequently up-regulated on AML blasts (Lynn et al, 2015) . Preclinical models using 4-1BBf CARTs exhibited potent leukaemia killing with preservation of healthy CD34 + cells. Of interest, the investigators used all trans retinoic acid (ATRA) to up-regulate the target antigen leading to improved anti-leukaemia activity. This general concept of increasing an antigen on diseased tissue to improve potency of an agent is likely to be further explored in the future. At this time, clinical data with CARTs in AML is limited compared to CLL and ALL, but this approach will probably gain more traction as further innovation in this expanding field takes place.
Building a better CART

Optimizing the starting material used to manufacture CARTs
The absolute number of CD4 + /CD8 + T cells, phenotypes
[na€ ıve (T N ), central memory (T CM ), or effector (T EM/EMRA )], detrimental effects from previous treatment regimens and intrinsic functional ability are variable between patients, and can significantly affect the ability to produce high quality CARTs. Several groups have shown in pre-clinical models and human translational studies that T N , T SCM , and T CM are more desirable than T EM/EMRA phenotypes as starting material for manufacturing CARTs given their more potent antitumour effects resulting from increased plasticity, expansion and functionality (Singh et al, 2016; Sommermeyer et al, 2016) . Enriching for desirable populations may be accomplished through a pre-manufacturing sorting process for physical separation, although this would be limited in some patients who have skewed starting material. Alternative methods of using combinations of interleukin-7 (IL7)/interleukin-15 (IL15)/interleukin-21 (IL21) in culture may be more ideal to expand and retain the more desirable less differentiated phenotypes (Sabatino et al, 2016; Xu et al, 2016) . Interestingly, it has been shown that antigen-experienced subsets directly promote the phenotypic, functional and metabolic differentiation of T N into T EM via Fas-FasL interactions during both ex-vivo and in-vivo cell expansion . The authors termed this phenomenon 'precocious differentiation', and demonstrated that disruption of Fas-FasL effectively maintains important primitive cell populations.
The ability of T cells to proliferate in response to stimulation, a hallmark of functional aptitude, differs between diseases as T cells from CLL patients are often very difficult to expand and demonstrate functional deficits compared to patients with ALL and healthy donors . While the reason for these cellular differences are not completely clear, explanations include many therapies common to CLL, including alkylators, fludarabine, steroids, and anti-CD52 may have long-term negative impact on T cells, and that T cells in CLL patients have been shown to be in a pseudo-exhausted state due to exposure to high antigen loads and immune-suppressive cytokines (Riches et al, 2013) . Ibrutinib, a Bruton tyrosine kinase inhibitor, has demonstrated outstanding efficacy in CLL, by targeting neoplastic B cells directly (Burger et al, 2015) , but also impacts T cells due to off target effect on inducible tyrosine kinase. It was anecdotally noted that patients on this drug long-term prior to enrolling on CART trials, had T cells that were easier to manufacture, and demonstrated good efficacy in three patients with CLL . Laboratory studies showed cells exposed to ibrutinib had increased number of doublings with stimulation, less PD-1 (also termed PDCD1) expression, and better cytokine production. Simply adding ibrutinib to culture could not reproduce this improvement, indicating prolonged exposure was required. To test this promising combinatorial approach at PENN we have initiated a pilot trial in CLL (NCT02640209).
The ability to harvest cells for manufacture directly from the donor in patients who have relapsed post allo-SCT would probably yield better material for manufacture as cells have been spared exposure to cytotoxic substances and the TME. Using this strategy, the NCI demonstrated feasibility as 4/5 patients with ALL and 1/5 patients with CLL achieved CR despite no lymphodepletion and, most importantly, there was no evidence of GVHD (Brudno et al, 2016) .
Another potential strategy would be the development of a readily available well defined product utilizing healthy T cells from universal donors, referred to as 'off the shelf CARTs'. The issue with this approach is the high degree of MHC mismatch, which would probably lead to rapid and lethal alloreactivity. It is now possible though transcription activatorlike effector nuclease (TALEN), clustered regulatory interspaced short palindromic repeats (CRISPR) or other evolving gene editing tools to efficiently remove MHC molecules, T cell receptors (TCRs), CD antigens and other proteins from donor T cells that theoretically would prevent overwhelming allo-reactivity. This concept was shown to be feasible in preclinical xenograft models using TALEN to eliminate the TRAC gene (TCR alpha/beta), and then CD52 to allow for alemtuzumab conditioning regimens in xenografts (Poirot et al, 2015) . It is likely that, over the next several years, clinical trials will evaluate this approach in humans and, if successful, would allow for greatly simplified manufacturing, logistics and widespread adoption of this therapy. However, 
Lessons learned from different CART19 constructs
As we accumulate more laboratory data and clinical experience with CARTs, it is becoming apparent that differently designed CARTs have unique properties for fighting cancer. It will probably require assimilating the strengths of each, with additional modifications, in order to optimize efficacy and safety (Fig 2) . While significant differences in trials make a direct comparison difficult, it appears that CARTs with 4-1BB domains have the potential to persist on the magnitude of years while CD28 CARTs are limited to several months (Davila et al, 2014; Maude et al, 2014; Porter et al, 2015) . This finding may be partly explained by the interplay between scFvs, co-stimulatory domains, intra-cellular signalling, cellular metabolism and resulting exhausted phenotype. Most CAR constructs appear susceptible to varying degrees of antigen-independent tonic signalling due to receptor clustering, which leads to over-activation and early exhaustion of CARTs (Long et al, 2015) . As the hallmarks of exhaustion are poor proliferative capacity, decreased cytokine production, increased inhibitory receptors, altered transcription profiles and increased rates of apoptosis (Wherry, 2011) , this would be expected to lead to a less vigorous CART with reduced tumour immunity. Notably, CARTs to CD19 did not appear to be susceptible to this antigen independent phenomenon, but in-vivo high antigen burdens that lead to chronic CAR activation could theoretically invoke the same chronic signalling and outcome. Early distortion of metabolism within T cells may lead to their inability to meet the bioenergetics demands of their effector function, and serve as an upstream driver of T cell exhaustion (Bengsch et al, 2016) . It has been found that co-stimulatory endo-domains differentially augment or ameliorate this process through modification of bioenergetics and mitochondrial biogenesis which impacts cell phenotype, proliferation, and persistence (Kawalekar et al, 2016) . The biological and clinical differences observed between CARTs containing different co-stimulatory domains supports the hypothesis that outcomes could be further improved with further manipulation of these co-stimulatory domains. The 4-1BB co-stimulatory domain appears to allow CARTs to run a marathon, while CD28 prepares them to run a sprint but then burn out. It might be that a mix of CARTs with these co-stimulatory domains is most ideal to mimic natural immune response leading to the best short and long-term tumour immunity, although this would need to be studied.
Preventing CD19 negative relapse
Loss of CD19 on leukaemic cells has been shown to be due to alternatively spliced variants with a compromised epitope (Sotillo et al, 2015) , or switch to a myeloid phenotype Jacoby et al, 2016) . These escapes occur due to the pressure that CARTs place on leukaemic cells that leads to natural selection similar to antibiotics leading to resistant microorganisms. Using a 'CART cocktail' that contains T cells for multiple antigens, for example, against CD19 and CD123 to treat B cell ALL, a single T cell that can express multiple CARs for different antigens, or a single bispecific CAR could potentially decrease the chance of tumour escape .
Optimizing the safety of CARTs
The ability to remove CARTs causing toxicity would provide an additional safety net. Mechanisms being explored include (i) inducible caspase 9 system where a small molecule (AP1903) drug dimerizes caspase 9 pro-molecules so that apoptotic pathways are induced (Di Stasi et al, 2011); (ii) transducing genes for CD20 or EGFR so that antibody therapy with rituximab or cetuximab respectively deletes cells; (iii) HSV thymidine kinase incorporation so that the prodrug ganciclovir leads to elimination (Casucci et al, 2013) ; (iv) transient CAR expression by using mRNA (Riet et al, 2013) . While these mechanisms would improve our ability to treat toxicity when it occurs, they would also lead only to a transient presence of CARTs. Therefore, the up-front prevention of off tumour toxicity to healthy tissues is imperative. One potential solution would be requiring CARTs to recognize combinatorial antigens by using a synthetic NOTCH receptor for one antigen that then drives the inducible expression of a CAR specific for a second antigen so that a cell must express 2 antigens to 'arm and activate' the CARTs (Roybal et al, 2016) . Other strategies have looked to use 'tumour sensing' where T cells are transduced with a CAR that provides suboptimal activation upon binding its antigen, but a chimeric co-stimulatory receptor that recognizes a second antigen leads to activation (Kloss et al, 2013) . Lastly, using a CART that requires a small molecule drug to activate an 'ON-switch' so that antigen binding and intracellular signalling components only assemble in its presence is an interesting approach . These strategies of requiring multiple antigens or additional signals for CART activation could allow for amplified discriminatory power between tumour and normal tissue, thereby increasing the landscape of targetable antigens, which may be especially applicable to AML.
A tough road for CARTs to travel: overcoming immune roadblocks
Regulatory cells, suppressive cytokines, chemical mediators (e.g., indoleamine 2,3-dioxygenase, IDO), stromal barriers and inhibitory immune checkpoint ligands found with the TME are toxic to T cells (Joyce & Fearon, 2015) . The PD-1/ PD-L1 (PDCD1/CD274) axis plays an important role in many haematological malignancies based on high response rates seen clinically to antibody blockade (Ansell et al, 2015; Lesokhin et al, 2016) . It is likely that CARTs, like regular T cells, are inhibited by PD-L1 expression, and that administration of anti-PD-1 blockade may interrupt this interaction leading to increased CART cytotoxicity (Cherkassky et al, 2016) . To our knowledge this approach is being evaluated in clinical trials for lymphoma (NCT02650999), but there are no clinical trials in leukaemia at this time. Rather than rely on antibody blockade, it may be feasible to use genetic editing tools to disrupt PD-1 expression on T cells so as to dampen inhibitory signalling (Su et al, 2016) . Another possibility is utilization of switch receptors that incorporate a piece of the PD-1 receptor into the CAR construct in order to cause PD-L1 expression within TMEs to paradoxically augment CART cytokine secretion, proliferation and granzyme expression, resulting in better tumour control . Further modifications, including TGFb dominant negative receptors (Zhang et al, 2013) , constitutive CD40 ligand expression (Curran et al, 2015) , co-administration with IDO inhibitors (Ninomiya et al, 2015) or Building a better chimeric antigen receptor T cell. Ab, antibody; Ag, antigen; CAR, chimeric antigen receptor; CARTs, chimeric antigen receptor T cells; HLA, human leucocyte antigen; HSV, herpes simplex virus; iCasp9, inducible caspase 9; IL12, interleukin-12;IL15, interleukin -15; IL21, interleukin-21;IL7, interleukin-7; LAG3, lymphocyte activating 3; mRNA, messenger ribonucleic acid; PD1, programmed death 1; T CM, central memory T cell; TCR, T-cell receptor; tEGFR, truncated epidermal growth factor receptor; TGFb DNR, transforming growth factor beta dominant negative receptor; T N, na€ ıve T cell; TRUCKS, T cells redirected for universal cytokine-mediated killing T SCM , T memory stem cells. 'armoured CARTs' that produce IL12 (Chmielewski et al, 2011) , to confer resistance to the microenvironment will further pave the road for CARTs.
Conclusions and perspective
The on-going success of CART19 in B cell malignancies fuels the desire to build even better CARTs, and to develop CARTs that successfully and safely target 'less ideal' antigens as is needed in AML. Differential outcomes for CD19 targeting CARTs between CLL and ALL illustrate unique challenges to overcome in different patient populations treated with the same investigational CART product. In ALL, initial remission rates are outstanding, but many patients will ultimately relapse with disease. Conversely, CR rates in CLL are lower, but remarkably durable. Reasons for these differential outcomes between ALL and CLL patients receiving the same agent are complex, and not completely understood at this time, but, as discussed, strategies are already being investigated to overcome these challenges. There are also opportunities to make intrinsic changes in the investigational product through optimizing CAR constructs and the population of T cells transduced. In addition, extrinsic ways to improve CART performance include preventing T cell inhibition that may occur in the TME with co-administration of checkpoint inhibitors or ibrutinib, and modifications to clinical trial design with regards to lymphodepletion, timing and dose of CARTs administration. Despite common antigens found between malignancies, there may actually be no one CART or treatment paradigm that fits all scenarios, requiring further honing of this 'precision medicine'. The optimal position of CARTs in treatment algorithms and its relation to allo-SCT for each type of cancer can be expected to continually evolve as this immunotherapeutic strategy gains traction and speeds ahead.
